Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 11/20 | 0.52 |
| ▸ | KYAT1 | Q16773 | 2/20 | 0.52 |
| ▸ | KYAT3 | Q6YP21 | 2/20 | 0.52 |
| ▸ | GOT1 | P17174 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073069 | 0.82 | PYGL (0.47) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL4064973 | 0.81 | AADAT (0.60) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL5629416 | 0.81 | CACNA1S (0.57) | AADATKYAT1KYAT3GOT1CACNA1S | |
| SCHEMBL5628897 | 0.81 | AADAT (0.52) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL4064396 | 0.80 | AADAT (0.51) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL4242434 | 0.79 | AADAT (0.57) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL4069787 | 0.78 | AADAT (0.50) | AADATKYAT1KYAT3GOT1CACNA1S | |
| Hydrochloric Acid SCHEMBL6529083 | 0.78 | MEN1 (0.35) | AADATKYAT1KYAT3GOT1PYGL | |
| SCHEMBL27542522 | 0.77 | AADAT (0.55) | AADATKYAT1KYAT3GOT1CACNA1S | |
| SCHEMBL4071608 | 0.76 | AADAT (0.48) | AADATKYAT1KYAT3GOT1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-1819332-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LTD (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-7276517-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7276517-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-7276517-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-7129249-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1483270-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074532-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043069-A1 | 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans | PYGL, PYGM, GYS1 | AADAT 3906/4885KYAT1 2912/4885KYAT3 1619/4885 |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | AADAT 4266/4885KYAT1 3914/4885KYAT3 2553/4885 |
| US-20090099176-A1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PC, GOT2, PDK1 | AADAT 426/4885KYAT1 542/4885KYAT3 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.